Not the MOA, It’s the Molecule That’s Unique
Yes, the mechanism of action of Anavex 2-73, how it works within the neuron, may not be unique. There may be other sigma-1 receptor angonists. But none of consequence have ever been elaborated upon here by anyone, beyond the Anavex pipeline molecules.
The significance of the Anavex 2-73 mechanism of action in regards to both Central Nervous System patients and to Anavex equity investors (among others) is not that it works in ways like no other, that it has a unique mechanism of action. Instead, it is unique because IT WORKS.
Unless other sigma-1 receptor agonists can match or exceed the demonstrated safety and efficacy profiles of Anavex 2-73 against the various Central Nervous System diseases against which it is targeted, the mechanism of action criticism is a convenient straw man to push or blow over, of no consequence.
The seminal question is not the uniqueness of the Anavex 2-73 mechanism of action whatsoever. Solely, it’s a question of whether or not the drug safely and effectively treats Central Nervous System diseases.
Many of us here, based upon the copious murine and yet-fragmentary human data, coupled with the explanatory mechanism of action (restoration of neuron homeostasis by re-connecting mitochondria and endoplasmic reticula to allow normalized ATP supply and C++ transport and signaling), have the greatest confidence in eventual FDA approval for one or more profound Central Nervous System diseases.
Others are not so convinced, or even entirely skeptical, awaiting confirmatory Phase 3 clinical trials data next year.
The uniqueness of Anavex 2-73's mechanism of action in the treatment or prevention of central nervous system diseases is not an issue of concern whatsoever. Whether or not it safely and efficaciously works is the actual issue. So far, the data point strongly in those two directions. No other drug or molecule has even been hinted to possess equivalent or competitive traits.
If there is one, let’s hear about, regardless of its particular mechanism of action. Right now, there’s only one ball game going on, with Anavex 2-73 on the field. The game rules are the same for all competitors, the restoration of neuron homeostasis by the mechanism of action of re-connecting and restoring mitochondrial and endoplasmic reticular functions. The only balls in play in this game belong to Anavex. Their molecules, are, unique. And they've already racked big scores. This championship came ends later this year or early next, with the box score posting of any of the three human trials soon to commence.
Those of us with AVXL positions will wear our Alzheimer's Treatment Tournament championship rings with pride and delight --- sometimes shaking the hands of CNS disease patients whose lives will have been so much improved or saved.
